We previously reported that an equimolar combination of resveratrol, quercetin and catechin (RQC) inhibits the PI3K/Akt/mTOR signaling pathway and breast cancer progression in vitro, and in vivo, and can act as a chemosensitization agent for anti epidermal growth factor receptor (EGFR) targeted therapy [11,24,25]. Here, EGFR is linked to breast carcinoma.